Atara Biotherapeutics

#Cell Therapy #Oncology #Autoimmune Disease #Solid Tumors

Clinical-stage cell therapy company developing allogeneic, off-the-shelf T-cell immunotherapies for EBV-driven cancers and autoimmune diseases, including tab-cel (tabelecleucel) and next-generation CAR-T programs.

Company Info

Sector:Cell Therapy

Headquarters:Thousand Oaks, California, USA

Founded:2012

Website:www.atarabio.com/

Clinical Development Pipeline

tabelecleucel (tab-cel)

Target: EBV-infected B cells

EBV+ post-transplant lymphoproliferative disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ATA3219

Target: CD19

B-cell malignancies and autoimmune disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

Pascal Touchon

President and Chief Executive Officer

Eric Hyllengren

Chief Financial Officer

K. Amar Murugan

Chief Legal Officer

Careers & Job Openings

See all open roles

All departments

Various

Apply Now →